Generic Name and Formulations:
Measles, mumps, rubella, and varicella viruses live, attenuated; lyophilized pwd for SC inj after reconstitution; contains neomycin (trace), human albumin; preservative-free.
Merck & Co., Inc.
Indications for PROQUAD:
Measles, mumps, rubella, and varicella immunization; may be used if a 2nd dose of measles, mumps, rubella, and varicella vaccine is needed.
Give SC in deltoid area or upper anterolateral thigh. <12 months or ≥13yrs: not recommended. 12 months–12yrs: 1 dose of 0.5mL. If a 2nd dose is needed, give at 4–6yrs.
Egg, gelatin, or neomycin hypersensitivity. Blood dyscrasias. Leukemia, lymphoma, or other bone marrow or lymphatic malignancy. Primary or acquired immunodeficiency. Family history of congenital or hereditary immunodeficiency. Immunosuppressant therapy. Active untreated tuberculosis. Fever >101.3°F. Pregnancy (Cat.X); avoid pregnancy for 3 months after vaccination.
Have epinephrine inj (1:1000) available. History of febrile convulsions or cerebral injury. Thrombocytopenia. Avoid contact with high-risk individuals susceptible to varicella for 6 weeks after vaccination. Post-exposure prophylaxis for measles, mumps, rubella, or varicella. HIV-infected children. Contains albumin; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease). Nursing mothers: not recommended.
Immunosuppressants (see Contraindications). Avoid salicylates for 6 weeks after vaccination. Defer vaccination for at least 3 months after blood or plasma transfusions or immune globulins. Avoid immune globulin administration for 1 month after vaccination. Separate dosing of measles-containing vaccine by 1 month. If 2nd dose of varicella-containing vaccine needed, separate by 3 months. Concomitant other vaccines: see full labeling. May interfere with tuberculin skin test.
Inj site reactions, fever, irritability, rash; others.
Report adverse events to VAERS by calling (800) 822-7967.
Single-dose vials—10 (w. diluent)
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Cochrane Data Release and the Case for "Open Science"
- Rates of Incident Type 2 Diabetes in Chronic Kidney Disease
- Characteristics of Acquired Partial Lipodystrophy With Metabolic Abnormalities
- Poor Glycemic Control Associated With Higher Risk for Dementia in Older Adults With T1D
- Shift Seen From EDs to Urgent Care for Low-Acuity, Acute Care